The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Regulatory News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 365.00
Bid: 360.00
Ask: 370.00
Change: -2.00 (-0.54%)
Spread: 10.00 (2.778%)
Open: 365.00
High: 365.00
Low: 365.00
Prev. Close: 367.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Increase to Block Listing

21 Jan 2021 14:49

RNS Number : 5100M
MaxCyte, Inc.
21 January 2021
 

 

 

 

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

 

Increase to Block Listing,

 

Block Listing Return

 

and

 

Total Voting Rights

 

 

 

MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, announces that application has been made for admission to trading on AIM in respect of an additional block listing of 942,900 common stock of $0.01 each in the capital of the Company ("Common Stock") to become effective on 27 January 2021.

 

The Common Stock may be issued pursuant to the exercise of share options under the Company's Long-Term Incentive Plan (the "LTIP") and will, upon issue, rank pari passu in all respects with the Company's existing Common Stock. Following this increase, the total Block Listing will consist of 1,000,000 Common Stock.

 

 

AIM Block Admission Return

 

MaxCyte also makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.  

 

a. Name of company

 

MaxCyte, Inc.

 

b. Name of scheme(s)

 

MaxCyte Long Term Incentive Plan

 

c. Period of return:

 

From: 1 July 2020 To: 21 January 2021

 

d. Number and class of securities not issued under scheme

 

319,263 ordinary shares of common stock of $0.01 each

 

e. Number of shares issued under scheme during period

 

262,163 ordinary shares of common stock of $0.01 each

 

f. Balance under the scheme not yet issued at the end of the period.

 

57,100 ordinary shares of common stock of $0.01 each

 

g. Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission; If additional block listing application have been made, under this scheme, since the original listing application please also state the number of shares and the date(s) of admission.

 

1,000,000 ordinary shares of common stock of $0.01 each on 5 May 2017

 

Please confirm your total issued share capital as at the end of this period.

(If you hold any shares in Treasury state the figure separately);

 

 

The total issued stock capital of the Company is 77,422,169 shares of Common Stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 67,522,080 and the number of restricted shares of Common Stock trading under the symbol 'MXCS' is 9,900,089.  

 

 

Treasury shares (if applicable) ………Nil………….

 

h. Contact name and telephone number for queries;

 

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Accounting Officer

+1 301 944 1660

 

Date

 

21 January 2021

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRPPUMCGUPGGCG
Date   Source Headline
5th Sep 20231:05 pmRNSBaird Global Healthcare Conference Participation
4th Sep 20231:32 pmRNSTR-1: Notification of major holdings
4th Sep 20237:00 amRNSTotal Voting Rights
1st Sep 20239:01 amRNSExercise of options and PDMR dealing
18th Aug 20235:25 pmRNSTR-1
17th Aug 20234:27 pmRNSTR-1: Notification of major holdings
17th Aug 20237:00 amRNSTR-1: Notification of Major Holdings
10th Aug 20237:25 amRNSFiling of Form 10-Q
10th Aug 20237:00 amRNSSecond Quarter and Half-Year Results
8th Aug 20233:15 pmRNSTR-1: Notification of major holdings
7th Aug 20235:01 pmRNSTotal Voting Rights and Block Listing Return
1st Aug 20231:05 pmRNSStrategic Platform License with Prime Medicine
31st Jul 20235:26 pmRNSExercise of options and PDMR dealing
26th Jul 20232:31 pmRNSTR-1: Notification of major holdings
24th Jul 20235:08 pmRNSTR-1: Notification of major holdings
24th Jul 20235:06 pmRNSTR-1: Notification of major holdings
13th Jul 20231:05 pmRNSNotice of Second Quarter 2023 Financial Results
11th Jul 20237:00 amRNSTR-1: Notification of major holdings
10th Jul 20231:05 pmRNSSigning of Strategic Platform License
10th Jul 20237:00 amRNSTR-1: Notification of major holdings
7th Jul 20239:23 amRNSTotal Voting Rights
6th Jul 20234:41 pmRNSTR-1: Notification of major holdings
6th Jul 20231:05 pmRNSSigning of Strategic Platform License
29th Jun 20233:19 pmRNSTR-1: Notification of major holdings
29th Jun 20237:00 amRNSTR-1: Notification of major holdings
29th Jun 20237:00 amRNSExercise of options and PDMR dealing
23rd Jun 20233:46 pmRNSGrant of Options
23rd Jun 20237:17 amRNSResult of AGM
23rd Jun 20237:00 amRNSResult of AGM
21st Jun 202310:10 amRNSPublication of Annual Report
16th Jun 202312:32 pmRNSExercise of options and PDMR dealing
2nd Jun 20237:00 amRNSUpcoming Investor Conferences
1st Jun 20237:00 amRNSTotal Voting Rights
11th May 20237:22 amRNSFiling of Form 10-Q
11th May 20237:00 amRNSFirst Quarter Financial Results
9th May 20237:00 amRNSExercise of options and PDMR dealing
4th May 20231:05 pmRNSSigning of Strategic Platform License
3rd May 20234:22 pmRNSDirector/PDMR Shareholding
13th Apr 20237:00 amRNSNotice of First Quarter 2023 Financial Results
30th Mar 202312:46 pmRNSDirector/PDMR Shareholding
28th Mar 20237:00 amRNSAppointment of Chief Financial Officer
22nd Mar 20237:00 amRNSGrant of Options and PDMR Dealing
16th Mar 20237:01 amRNSFiling of Form 10-K
16th Mar 20237:00 amRNS2022 Full Year Results
8th Mar 20231:00 pmRNSEstablishment of New Scientific Advisory Board
7th Mar 20237:00 amRNSPreliminary Unaudited Q4 &FY 2022 Revenue Results
6th Feb 20233:40 pmRNSDirector/PDMR Shareholding
2nd Feb 20237:00 amRNSNotice of Results
30th Jan 20237:00 amRNSExercise of options and PDMR dealing
4th Jan 20237:00 amRNSSigning of Strategic Platform License

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.